Fiocruz, TB Alliance and Viatris sign Memorandum of Understanding to strengthen domestic manufacturing capacity for tuberculosis prevention and treatment
The Oswaldo Cruz Foundation (Fiocruz), the global nonprofit organization TB Alliance, and Mylan Laboratories Limited, a subsidiary of global healthcare company Viatris Inc. (Nasdaq: VTRS), signed a Memorandum of Understanding (MoU) on November 16 to strengthen Brazil’s domestic manufacturing capacity for tuberculosis prevention and treatment.
The MoU expresses the parties’ intention to explore future collaboration in research, technological development, manufacturing, and the assessment of potential technology transfer opportunities for innovative tuberculosis medicines in Brazil. The cooperation aims to expand access to medicines provided through Brazil’s Unified Health System (SUS).
The initiative will be led within Fiocruz by its Institute of Drug Technology (Farmanguinhos/Fiocruz).
“Over the years, the adoption of priority strategies and the incorporation of new technologies into the SUS have strengthened efforts to combat tuberculosis. Farmanguinhos contributes directly through research and development projects and by supplying key tuberculosis medicines distributed through the SUS. This cooperation brings us closer to international organizations with complementary expertise and extensive experience in combating tuberculosis, with a focus on identifying and addressing gaps in access to treatment,” said Silvia Santos, Director of Farmanguinhos/Fiocruz.
The partnership reflects TB Alliance’s commitment to expanding local manufacturing and building more resilient supply chains, helping ensure that effective and affordable treatments reach everyone who needs them as quickly as possible.
“Brazil has long demonstrated leadership in public health research and innovation, and our partnership with Farmanguinhos/Fiocruz builds on this expertise to advance our shared goal of ending tuberculosis,” said Mel Spigelman, MD, President and CEO of TB Alliance.
“Through collaboration with Fiocruz and Viatris, TB Alliance is pleased to support Brazil’s efforts to translate scientific advances into sustainable access to better tuberculosis treatments, saving lives and laying the groundwork for future innovations.”
“We are pleased to collaborate with TB Alliance and Farmanguinhos/Fiocruz to support the development of a sustainable, long-term supply of tuberculosis treatments for patients. This initiative reflects our shared commitment to expanding access to essential medicines and improving health outcomes for communities affected by tuberculosis,” said Arvind Kanda, Head of India Markets and Access (Antiretrovirals, India, South Africa and Sub-Saharan Africa) at Viatris.
According to the World Health Organization (WHO), approximately 10.6 million people developed tuberculosis worldwide in 2025, resulting in 1.13 million deaths.
In Brazil, 84,368 new tuberculosis cases were reported in 2025, along with 6,376 deaths in 2024, according to the Brazilian Ministry of Health. These figures underscore the continued importance of tuberculosis as a public health priority and the need to expand access to treatment.
